Identification of novel 3-aryl-1-aminoisoquinolines-based KRASG12C inhibitors: Rational drug design and expedient construction by C H functionalization/annulation
作者:Zirong Gong、Yu Zhao、Buyi Xu、Zhou Yang、Boquan Ren、Han Yang、Chengfu Zeng、Renqiang Chen、Yan-Jun Xu、Qing Li
DOI:10.1016/j.bioorg.2023.106954
日期:2024.1
direct monoCH functionalization/annulation cascade reaction of amidines and sulfoxonium ylides was then developed with high versatility of substrates and good tolerance for polar functional groups. By using this reaction, the target compounds 1-amino-3-aryl isoquinolines were facilely prepared. Further in vitro tests led to identification of two novel lead compounds with KRASG12C inhibitory activity
开发一种合成方法来方便地构建具有所需生物活性的特定药物支架仍然具有挑战性。在此,我们描述了在 KRAS G12C抑制剂合成中合理应用合成方法的工作。新型 KRAS G12C抑制剂最初采用基于结构的药物设计策略,采用 1-氨基-3-芳基异喹啉支架进行设计。钌催化的直接单晶 C 随后开发了脒和硫鎓叶立德的H官能化/成环级联反应,具有底物的高通用性和对极性官能团的良好耐受性。利用该反应,很容易制备出目标化合物1-氨基-3-芳基异喹啉。进一步的体外测试鉴定出两种具有 KRAS G12C抑制活性的新型先导化合物。